<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161053</url>
  </required_header>
  <id_info>
    <org_study_id>Encephalopathy</org_study_id>
    <nct_id>NCT04161053</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy</brief_title>
  <official_title>Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical Study Evaluating the Efficacy and Safety of Nitazoxanide in preventing recurrence of
      Hepatic Encephalopathy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">November 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of encephalopathy episodes during treatment</measure>
    <time_frame>6 months</time_frame>
    <description>The number of encephalopathy episodes during treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>550 mg Rifaximin tablets twice daily for six months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Nitazoxanide tablets twice daily for six months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin 550 mg twice daily for 6 months</description>
    <arm_group_label>Rifaximin</arm_group_label>
    <other_name>Gastrobiotic, Trencedia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide 500 mg twice daily for 6 months</description>
    <arm_group_label>Nitazoxanide</arm_group_label>
    <other_name>Nanazoxid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cirrhotic patient with at least one previous episode of hepatic encephalopathy.

          -  Adult Patients aging from 20 to 65 years old

        Exclusion Criteria:

          -  Active GIT bleeding.

          -  Major psychiatric illness (psychosis &amp; epilepsy).

          -  Renal insufficiency (S.Cr 2mg/dl).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khadija Ahmed Glal, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>faculty of pharmacy- Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarek Mohamed Mostafa, ass, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>faculty of pharmacy- Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherief Abd-Elsalam, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University - Tropical Medicine Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, ass. prof.</last_name>
    <phone>00201147773440</phone>
    <email>sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>sherief abd-elsalam, ass. prof.</last_name>
    <phone>00201147773440</phone>
    <email>sherif_tropical@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-Elsalam</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Ass. Prof. Tropical Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

